Janet Kwiatkowski
Pediatric Hematology-Oncology · Philadelphia, PANPI 1093738833
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Agios Pharmaceuticals, Inc. at 35.4% of the total. Reporting peaked in 2022 at $17,316 and has fallen 82.2% since, to $3,085 in 2025. Among pediatric hematology-oncology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $1146.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$23K
- Chiesi USA, Inc.$18K
- Bristol Myers Squibb$11K
- Novo Nordisk Health Care AG$5K
- Regeneron$4K
- Biomarin Pharmaceutical Inc.$2K
- plus $2K from 4 others
Across 298 payments — averaging $12,251 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genetix Biotherapeutics Inc$2.4M
- Vertex$637K
- Agios Pharmaceuticals, Inc.$425K
- Global Blood Therapeutics, Inc.$36K
- Pfizer$36K
- Novartis$31K
- plus $36K from 4 others
What the payments were for
- Consulting fees$31,11948%
- Speaking & faculty fees$31,23548%
- Travel & lodging$1,8773%
- Food & beverage$1,1282%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 32 | $23,121 |
| Chiesi USA, Inc. | 7 | $18,045 |
| Bristol Myers Squibb | 8 | $10,781 |
| Novo Nordisk Health Care AG | 3 | $5,000 |
| Regeneron | 2 | $4,145 |
| Biomarin Pharmaceutical Inc. | 1 | $2,400 |
| Vertex | 1 | $1,698 |
| Apo-pharma Inc. | 1 | $125 |
| Genetix Biotherapeutics Inc | 1 | $24 |
| Abbott | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FERRIPROX$16,993
- PYRUKYND$9,089
- Luspatercept$8,948
- TIBSOVO$5,587
- Reblozyl$1,779
How this compares
$65,360 in reported general payments places this provider in the 90th percentile of 139 pediatric hematology-oncology providers in Pennsylvania.
See all pediatric hematology-oncology providers in Pennsylvania →
Other pediatric hematology-oncology in Philadelphia
- Stephan GruppPhiladelphia$390K
- Samuel BlackmanPhiladelphia$265K
- Sarah TasianPhiladelphia$90K
- Lindsey GreenePhiladelphia$90K
- Katherine HighPhiladelphia$63K
- Michele LambertPhiladelphia$62K
- Nataly ApollonskyPhiladelphia$57K
- Leslie RaffiniPhiladelphia$52K
- Michael FisherPhiladelphia$45K
- David TeacheyPhiladelphia$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.